As Molecular Cancer Therapeutics enters its fifth year of publication, I would like to thank the authors who have chosen the journal as a publication venue for their work, as well as the readers who have found the journal to be a vital forum for research on targets, therapeutics, and development. Over the last four years, manuscript submissions and published pages have more than doubled, and the journal's impact factor now ranks among the top 20 of 123 oncology journals. On behalf of the Deputy and Senior Editors and the AACR, I thank you for your continued support of MCT.
While we are proud of the high quality of the science published in MCT, the Editors recognize the value of special content such as Reviews and Commentaries to place that science into context. To that end, beginning with this issue, we are pleased to launch a series of review articles in the field of drug development. Contributed by leading experts in several critical fields, these reviews examine the latest developments in translational research and highlight key issues in the drug development process, focusing on promising therapeutic targets.
In this issue, in the first review of the series, Dario Altieri discusses why survivin sits at the crossroad of many key signaling pathways and may prove to be a master target for new therapeutics (1). In future issues, the series will continue with reviews on topics such as biomarkers, regulatory affairs, randomized discontinuation, imaging, diagnostics, new models, and promising new technologies.
We hope you find this new series useful and, as always, we welcome your comments on the reviews, as well as your suggestions for future topics. We look forward to your feedback and to your continued participation in the success of Molecular Cancer Therapeutics.
RSS Feeds